Algeta celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Norway. Not intended for US media. Oslo, Norway, 20 June 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, today celebrates the official opening of its commercial production facility for Xofigo® (radium Ra 223 dichloride) at the Institute for Energy Technology (IFE) in Kjeller, Norway. Read more
Originally only a small team, Algeta remains true to its heritage while steadily expanding into a global oncology company.
Read more
The Algeta Annual Report 2012 is now live! Find out more about the company’s progress over the past 12 months.
To the Annual Report
Algeta recognises that its corporate potential will only be fulfilled through collaborations.
Read moreAlgeta’s 1Q 2013 financial results are available
Algeta presented its First Quarter results on 15 May 2013, and the associated webcast can be accessed below.
The Algeta share is listed on the Oslo Stock Exchange under the ticker code ALGETA. All shares are freely transferable.
Algeta annually reviews the principles of corporate governance and how they are being implemented in the Group.
You are now leaving www.algeta.com. Links to sites outside of Algeta are provided as a resource to the viewer. Algeta accepts no responsibility for the content of linked sites.